Novel approaches in AML seek to overcome the challenges of the past and improve clinical outcomes.
Update on Kura Oncology's progress with tipifarnib and their emerging pipeline
Following the recent failure of Incyte's itacitinib in acute GVHD, we look at promising early developments following in their wake.
TIM-3 may have a role to play in myeloid hematologic malignancies such as AML and MDS. We explore the scientific rationale, competitive landscape, and initial clinical data.
Some novel targets, new agents and some twists in the tale to consider in hematologic malignancies
A look at what happened from the DREAMM1 to DREAMM2 trials exploring the BCMA ADC belantamab mafadotin in refractory multiple myeloma and why GSK have a challenge ahead
A look at some of the highly ranked clinical data presented over the weekend in Orlando
Science Friday at ASH19 with a look at various lymphoma and myeloma developments
A look at new developments in the KRAS niche and also a potential emerging novel target in addressing the development of acquired resistance.
A look at off Broadway abstracts on early new product development and scientific findings of interest
Non-T cell based immunotherapies that could be promising in hematologic malignancies
Some hidden gems and under the radar abstracts that may appeal to the off-Broadway crowd at ASH19
It's time for an update on new participants to the runners and riders in CLL and NHL. Some interesting findings with BTK inhibitors to consider here!